Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Abbott quarterly profit rises 28.3% on strong sales of COVID-19 tests

10/21/2020 | 07:34am EST

Oct 21 (Reuters) - Abbott Laboratories posted a 28.3% rise in third-quarter profit on Wednesday, helped by strong sales of COVID-19 tests and strength in its nutrition and diabetes businesses.

The company's net earnings rose to $1.23 billion, or 69 cents per share, in the quarter ended Sept. 30, from $960 million, or 53 cents per share, a year earlier. (Reporting by Manojna Maddipatla and Trisha Roy in Bengaluru; Editing by Arun Koyyur)


© Reuters 2020
All news about ABBOTT LABORATORIES
11/21ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
11/19ABBOTT LABORATORIES : Becomes first anchor sponsor of american diabetes associat..
AQ
11/18ABBOTT LABORATORIES : Launches the first infant formula in canada with an ingred..
AQ
11/17ABBOTT LABORATORIES : Launches the First Infant Formula in Canada with an Ingred..
AQ
11/17ABBOTT LABORATORIES : Named industry sustainability leader for the eighth year i..
AQ
11/16HHS Official Says The Agency Has Responded To Every State That Has Requested ..
RE
11/16ABBOTT : Named Industry Sustainability Leader for the Eighth Year in a Row on th..
PR
11/13ABBOTT LABORATORIES : Entry into a Material Definitive Agreement, Termination of..
AQ
11/12ABBVIE : Vice Chairman, Chief Commercial Officer Carlos Alban to Retire
DJ
11/11ABBOTT LABORATORIES : Announces the u.s. launch of the ionicrf generator for use..
AQ
More news
Financials (USD)
Sales 2020 33 873 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 794 M - -
P/E ratio 2020 43,9x
Yield 2020 1,34%
Capitalization 191 B 191 B -
EV / Sales 2020 5,98x
EV / Sales 2021 5,20x
Nbr of Employees 107 000
Free-Float 88,9%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 118,44 $
Last Close Price 107,62 $
Spread / Highest target 20,8%
Spread / Average Target 10,1%
Spread / Lowest Target -23,8%
EPS Revisions
Managers
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES23.90%190 742
ALIGN TECHNOLOGY, INC.70.41%37 493
SARTORIUS STEDIM BIOTECH98.78%32 358
SYSMEX CORPORATION40.76%21 519
AMERISOURCEBERGEN CORPORATION21.28%21 079
BIO-RAD LABORATORIES, INC.44.60%15 912